CSNK2A1/CK II alpha Antikörper (AA 1-100)
-
- Target Alle CSNK2A1/CK II alpha (CSNK2A1) Antikörper anzeigen
- CSNK2A1/CK II alpha (CSNK2A1) (Casein Kinase 2 alpha 1 (CSNK2A1))
-
Bindungsspezifität
- AA 1-100
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser CSNK2A1/CK II alpha Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunofluorescence (IF), Proximity Ligation Assay (PLA)
- Verwendungszweck
- Mouse monoclonal antibody raised against a partial recombinant CSNK2A1.
- Sequenz
- MSGPVPSRAR VYTDVNTHRP REYWDYESHV VEWGNQDDYQ LVRKLGRGKY SEVFEAINIT NNEKVVVKIL KPVKKKKIKR EIKILENLRG GPNIITLADI
- Kreuzreaktivität
- Human
- Produktmerkmale
- Antibody Reactive Against Recombinant Protein.
- Immunogen
- CSNK2A1 (AAH11668, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
- Klon
- 3D9
- Isotyp
- IgG2a
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- In 1x PBS, pH 7.4
- Handhabung
- Aliquot to avoid repeated freezing and thawing.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
-
-
CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation." in: Cancer biotherapy & radiopharmaceuticals, Vol. 26, Issue 3, pp. 381-8, (2011) (PubMed).
: "
-
CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation." in: Cancer biotherapy & radiopharmaceuticals, Vol. 26, Issue 3, pp. 381-8, (2011) (PubMed).
-
- Target
- CSNK2A1/CK II alpha (CSNK2A1) (Casein Kinase 2 alpha 1 (CSNK2A1))
- Andere Bezeichnung
- CSNK2A1 (CSNK2A1 Produkte)
- Hintergrund
-
Full Gene Name: casein kinase 2, alpha 1 polypeptide
Synonyms: CK2A1,CKII - Gen-ID
- 1457
- Pathways
- SARS-CoV-2 Protein Interaktom
-